Mind Fountain - The Dynamic Memory External Fixator _DMEF_ Mind by niusheng11


									The Dynamic Memory External Fixator (DMEF)

         Mind Fountain – Medical Technology

                     May 2008
• The Problem           Current treatment of fractured long bones,
 particularly the tibia (lower leg), is expensive, has a long healing
 time, and can lead to a variety of complications.

• Target Population           It is estimated that the annual number of
 lower leg fractures in the U.S. is 225,000; in the U.K. 46,000; in
 Germany 63,000; in Canada 25,000; in Brazil 141,000; and in Japan
 98,000, to mention only a few countries.

• The Solution          We have developed a smaller, lighter, user-
 friendly Fixator requiring minimal surgical procedures, thus reducing
 the risk of infection or knee pain, common following intramedullary
 nail surgery.
          The device is ready to market
New Features of the Rev. Fixator:

•All Metric designed parts (industry standards)
•All aluminum parts (weight reduction)
•Greater intramedullary pin positioning angle
•Greater shaft positioning angle
•Collar rotation locking lever (prevents
•Ball spline post pinned to universal joint

•   Our device is NOT just another External Fixator, but is a tool that
    accelerates ossification – the natural formation of the callus (the body’s
    “bone glue”) at the appropriate healing stage.

•   Successful clinical trials were conducted at Hadassah Hospital in
    Jerusalem, which yielded the following astonishing results:

     – The device almost completely eliminates the risk of bone

     – The device reduces the treatment time of tibia fracture by 50%,
       compared to other fixators, thus, allowing for rapid return to normal
       weight bearing.

     – The device almost completely eliminates the need for physical therapy,
       once it is removed.

     – The device is extremely user-friendly to the orthopedic surgeons, who
       traditionally dislike external Fixators.
• A Money Saver            The substantial reduction in treatment and rehabilitation time will save
  millions of pounds & dollars, respectively, to the British NHS, American HMOs, and rural
  orthopedic practices.

   –   The device is competitively priced, offering an alternative to the more expensive
       intramedullary nail surgery.

• Patent      The device is currently registered in the U.S., Canada, the U.K., France, Germany,
  Italy, Switzerland, and Israel.

   –   With its new design improvements, we began processing a new patent, adding an additional
       20 years of protection.

• FDA and CE          It is a 510K device ,and we began the process of obtaining CE certification;

• Market     The device’s estimated market size in the U.S. is $250 million annually, with a similar
  sized market in Europe;

   –   The above revenue can be doubled by effective marketing aimed at taking over a portion of
       the current intramedullary surgery nails market of more than $½ billion a year in the U.S.

• Company         We will establish companies in the U.S. and U.K. with internationally renowned
  orthopedic surgeons as board members.

• Financing        To commercialize this device, we seek £1,100,000, while the company’s
  valuation is conservatively estimated at £4.5 million.
Skin Melanoma Detector

Mind Fountain – Medical Technology

            May 2008
                           The Problem
• The current accuracy rate of skin melanoma detection is about 65%
  among dermatologists and 50% among family and general
  physicians. Some studies rate the positive predictive value of
  current evaluations at as low as 20%.

• If melanoma is detected in its early stages, the patient is often cured
  by a wide and deep resection of the tumor.

• It would be of great benefit to patients if one could perform a non-
  invasive analysis prior to lesion surgical removal.
                     The Software Solution

• We developed groundbreaking software that already exhibits 87%
  detection accuracy.

• It is part of an inexpensive system that provides immediate
  evaluation of all new skin lesions.

• It provides a precise analysis of changes in dermatologic diagnostic
  ABCD parameters (asymmetry, border irregularity, colors, &

• It will make the distinction between benign and malignant tumors,
  thus, significantly reducing unnecessary surgical removal of benign

• It offers navigation capabilities for easy lesion follow-up and
  excellent body mapping.
                            +1                            +6



Dermoscopic Images are
sent via e-mail, website
upload, CD- ROM, or
diskette to the Analysis

                           The melanoma detection
                           software makes exact
                           calculations of each of
                           the ABCD parameters for
                           every mole.
                     Imaging Improvement
Our system uses dermoscopic imaging that can capture details beneath the
dermal layer, based on spectral imaging, originally developed for satellite

     Hardware Diagram
• Near-Perfection         We plan to maximize our software detection accuracy to reach – in
  combination with the new spectral imaging – up to 99% accuracy, by establishing an online
  database of prospective melanoma images.

• Patents       The software is patented in the U.S. and we are in the process of registering an
  international patent for the integration of the software and the new spectral imaging. The latter is
  patented in the US and internationally.

• Companies          We are about to set up an analysis and marketing company in the U.S. and the

• Marketing         Since the system is internet-based, the requests for our services could come from
  the U.S., U.K., Canada, and Australia, and in time from other countries around the world to
  capture part of the estimated more than £1 billion market.

• Savings       Our detection system could save tens of millions of pounds & dollars, respectively,
  to major health care providers such as the British NHS, American HMOs, and rural area medical

• Follow-up        Since individuals usually have more than one lesion and will require a follow-up,
  our system will send automatic e-mail and pre-recorded voicemail reminders to the referring
  physicians and their patients.

• Investment        We seek £1,250,000 based on the company’s valuation, which is estimated at
Female Incontinence Therapy Device
    Mind Fountain – Medical Technology

                May 2008
• The Problem          Some women’s pelvic floor muscles weaken,
 often leading to lack of urinary control.

• Target Population         The female urinary incontinence
 problem affects more than 17 million American women and a similar
 number in Europe.

• Traditional Treatment              The most commonly recommend
 method for re-strengthening these muscles is to practice Kegel
 exercises. However, half of the women affected do not know how to
 do it properly and the other half tend to stop after a short while.
• Our Solution          A device that aims to raise the quality of life for
 women who suffer from this condition by simplifying and improving
 the efficiency of treatment, thus easing the tremendous discomfort
 and embarrassment associated with female urinary incontinence.

•   Our device generates the desired muscle contractions by localized electrical stimulation, and is
    designed for optimal interface between the probe’s electrodes and the user’s pelvic floor muscles;

•   It is elegant, lightweight, compactly designed, user-friendly, self-manageable, simple to operate,
    painless, and safe for treating the 3 forms of incontinence: stress, urge, and mix;

•   It eliminates the need for continual readjustments by a physician;

•   It utilizes a non-irritant, medical grade silicon with superior characteristics, ensuring that it is
    comfortable, safe, and easy to clean;

•   Insertion and removal of the electrode probe is made easy due to its flexibility;

•   The probe’s geometry and flexure allow for optimal anatomical fit and prevent accidental self-
    extraction, regardless of whether the user is standing, sitting, stationary, or walking;

•   The probe will be offered in two sizes to fit the range of vaginal anatomies;

•   Our device’s innovative & discreet design, comfort, and ease of operation will contribute to
    overcoming the barrier to treatment by moving it out of a hospital and clinic environment and into
    the privacy and comfort of the user’s home.
•   Clinical Trials   The first round of trials was conducted in Israel that showed an overwhelming
    degree of user-compliance, cooperation and satisfaction;

     –   We are about to launch the second round of clinical trials at two urogynecological outpatient
         departments associated with: (1) Harvard Medical School in Boston and (2) Cedar Sinai
         Hospital – affiliated with U.C.L.A. in Los Angeles.

• Regulations           It is a 510K FDA device and during this visit to London, I have begun the
    process of obtaining CE certification.

• Patent          The device is patented in the U.S. and was just registered in Europe.

• Companies              We will establish our company in the U.S. and U.K.

• Market        In treating female urinary incontinence in the U.S., $2.5 billion annually is spent on
    diapers; $1 billion on surgery; $1 billion on medication; and $1 billion on devices, all which
    increases by 6% annually.

     –   Our device could, in time, replace a portion of the $4.5 billion diaper, surgery, and medication
         markets, given that each has drawbacks

     –   The low cost of the device to the end-user will make it affordable to almost all women,
         making it an attractive competitive alternative to other forms of treatment.

• Financing            We seek £1,500,000, while the company’s valuation is estimated at more than
    £5 million.

To top